AXL and hepatocellular carcinoma: It is noteworthy that the multi-tyrosine kinase inhibitor Cabozantinib, which targets Axl among other RTKs, is used as a third-line treatment option for patients with advanced HCC, supporting the potential clinical relevance of Axl in this disease [16].